Abstracts of the 14th Red Lara Taller General, Mérida, Mexico, 06-9 March 2019.

Table 1

Description of the cases.

	Age (years)	Number of aspirated follicles	Number of  oocytes recovered	Number of MII-stage oocytes
Mean ± SD	30.25±6.04	23.01±12.62	13.11±7.74	10.74±6.94
Ovarian stimulation protocol				Cases (N)
GnRH Antagonist + rFSH (Age: 28.21±6.24)				58
GnRH Agonist + rFSH (Age: 31.69±5.56)				72
GnRH Agonist + uFSH (Age: 31.50±5.37)				12

Category	Cycles Analysed	Average MII Oocytes	Blastulation rate	Average Euploid Blastocysts
<35	18	13.28	4.5	1.89
35-37	33	9.42	3.27	1.15
38-40	55	8.15	3.09	0.53
>40	44	8.18	2.27	0.29
Egg donor cycle	40	12.9	5.43	2.7

Table 1

Result and biopsy day

Biopsy day	Aneuploid	Euploid	Mosaic	Total
5	72 (51%)	59 (42%)	9 (7%)	140
5	173 (61%)	92 (33%)	76 (6%)	282
7	27 (68%)	9 (23%)	4 (10%)	40
Total	272 (59%)	160 (35%)	30 (6%)	462

Table 2

Result and age group

Age group	Aneuploid	Euploid	Mosaic	Total
<37	98 (54%)	70 (38%)	15 (8%)	183
≥37	174 (62%)	90 (32%)	15 (5%)	279
Total	272 (59%)	160 (35%)	30 (6%)	462

Table 1

Chromosome rearrangements that warranted PGT-SR cycles

	Chromosomal rearrangement	Total nº of couples	Chromosomal rearrangement	Total nº of couples
Reciprocal translocations	46, XY, t(8;9)(q10;p10)	1	46, t(3;10)(p25;q11.2)	1
	46, XY, t(6;20)(p21,3;q11,2)	1	46, XY, t(9;18)(q22;p11)	1
	46, XY, t(3;15)(p12;q14)	1	46, XX,t(10;18)(q11,2;q11,2)	1
	46, XY,t(5;15)(q35.1;q22.1)	1	46, XX, t(3;9)(q12;q13)	1
	46,XY,t(10;13)(q21.3;q21.2)	1	46, XY, t(2;12)(p13;q22)	1
	46, XY, t(2;5)(q21;p13)	1	46, XY, t(15;17)(q15;p13)	1
	46, XY, t(1;22)(p34;p13)	1	46, XY, t(1;14)(q25,3;q31)	1
	46,XY,t(10;13)(q21.3;q21.2)	1	46, XX, t(4;13)(p10,q10)	1
	46, XX, t(2;4)(p12;p14)	1	46, XY t(7;10)(q11.2;q22)	1
Robertsonian translocations	45, XX, t(13;14)(q10;q10)	2	45, XY, t(13;14)(q10;q10)	7
Insertion	46, XY; ins(7;8)(q35q36.3;p23.3)			1

Table 2

Embryo chromosome results of the PGT-SR cycles

Status for paternal translocation	Total	Euploidy	Aneuploidy	Mosaic
Balanced	66 (44.6%)	35 (23.6%)	21 (14.2%)	10 (6.8%)
Unbalanced	82 (55.4%)	49 (33.1%)	28 (18.9%)	5 (3.4%)

Table 1

Results from the different PGT-A indications

	Time to pregnancy	Recurrent pregnancy loss	Repeated IVF failure	Advanced maternal age	RPL + AMA
Cycles	132	41	41	181	15
Age rate	28.7±5.4	35.3±2.4	35.6±2.7	40.9±1.9	40 1±1.3
Euploidy rate	58.4%	50.7%	45.1%	27.1%	21.1%
Cycles with no euploid embryo	8.3% (11)	22% (9)	22% (9)	55.2% (100)	66.7% (10)
Number of transfers	124	33	39	48	21
Clinical pregnancy/transfer	56.5%	48.5%	38.5%	45.8%	42.9%
Miscarriage	5.1%	0%	18.8%	4.2%	30.0%

Table 1

Extracytoplasmatic dysmorphisms

	Summer 2017		Winter 2017		p
Pellucide Zone Thickness	144	73%	249	61%	0.04
Perivitelline Space Increased	37	19%	113	28%	0.017
Granulles in the Perivitelline Space	14	7%	64	16%	0.03
Oocyte Shape	14	7%	27	7%	0.823
Oocyte Color	18	9%	72	18%	0.006
Oocyte Size	3	2%	2	0%	0.189
Fragmented Pollar Body	60	30%	168	41%	0.11
Polar Body Size	1	1%	11	3%	0.07
Polar Body Shape	0	0	51	13%	<0.001

Table 2

Cytoplasmatic Dysmorphisms.

	Summer 2017		Winter 2017		p
Vacuoles	9	5%	7	2%	0.04
Reticulum	0	0%	7	2%	0.064
Refractile Bodies	14	7%	237	58%	<0.001
Gelatinous Cytoplasm	0	0%	46	11%	<0.001
Granules in the Cytoplasm	13	7%	172	42%	<0.001
Dark Coarse Granules	42	21%	48	12%	0.002

Table 1

Comparison of carrier frequencies for top 10 disorders observed in each panel

Panel A		Panel B		Panel C
Disorder	Carriers	Disorder	Carriers	Disorder	Carriers
GJB2-Related Nonsyndromic hearing loss and deafness	26	Familial Mediterranean Fever	14	Alpha-1 antitrypsin deficiency	14
Biotinidase Deficiency	19	CFTR-Related disorders	14	21-hydroxylase deficiency	11
Cystic Fibrosis	11	Wilson disease	14	Alpha thalassemia	8
Familial Mediterranean Fever	10	GJB2-Related Nonsyndromic hearing loss and deafness	7	CFTR-Related disorders	7
Pseudocholinesterase Deficiency	10	SMN1 Linked Spinal Muscular Atrophy	7	Familial Mediterranean Fever	7
SMN1 Linked Spinal Muscular Atrophy	8	Progressive familial intrahepatic cholestasis	7	Tyrosinemia type I	7
Hereditary Fructose Intolerance	6	Primary coenzyme Q10 deficiency	7	Oculocutaneous albinism type II	5
Type I Glutaric Acidemia	6	Muscular dystrophy-dystroglycanopathy type C3	7	SMN1 Linked Spinal Muscular Atrophy	5
Classical Galactosemia	5	Cystic Fibrosis	6	Glucose-6-phosphate dehydrogenase deficiency	5
Glycogen Storage Disease: Type II	5	Classical Galactosemia	6	GJB2-Related Nonsyndromic hearing loss and deafness	4

Table 1

Results.

Age SART Classification (years)	Insemination Technique
	FIV		ICSI		p-value
	Number of cycles	Fertilization Rate	Number of cycles	Fertilization Rate
Lower than 35	962	69% (6438/9389)	1027	71% (6324/8848)	<0.001
35-37	877	67% (4507/6715)	919	73% (4629/6373)	<0.001
38-40	874	68% (3721/5453)	940	72% (3931/5430)	<0.001
41-42	378	65% (1284/1981)	348	71% (1169/1636)	<0.001
Higher than 42	178	70% (472/679)	243	73% (691/950)	0.1727

Table 1

Outcome

Outcome	Fresh		Vitrified		p value
Laboratory Parameters	Mean	SD	Mean	SD
Number of oocytes received (n)	11.01	3.38	7.54	1.81	<0.0001
Number of inseminated oocytes (n)	9.48	3.23	7.14	1.72	<0.0001
Fertilization rate (%)	74.64	19.33	70.03	19.83	0.03
Mean number of transferable embryos	4.59	2.48	2.56	1.53	<0.0001
Blastocyst rate (%)	63.89	24.03	52.21	27.23	0,00
Reproductive Outcome	+ (n)/cycles (n)	%	+ (n)/cycles (n)	%	p value
Ongoing pregnancy rate* (First Transfer) (%)	133/298	44.63%	28/73	38.36%	0.329
Cumulative ongoing pregnancy rate* (%)	180/237	75.95%	30/61	49.18%	<0.0001

Ongoing pregnancy rate considers deliveries and positive ultrasounds to date.